Yes Chadman very good NEWS Dr. Yin Chen, CytoGenix' Vice President and Chief Scientific Officer, commented, "The introduction of CY403 into the preclinical product development phase within three months after target discovery and validation demonstrates the true value of our gene silencing technology. We have the capability to move very efficiently from discovery to product candidate in a matter of a few months
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.